| Record ID | marc_loc_2016/BooksAll.2016.part42.utf8:86950579:1485 |
| Source | Library of Congress |
| Download Link | /show-records/marc_loc_2016/BooksAll.2016.part42.utf8:86950579:1485?format=raw |
LEADER: 01485cam a22003618i 4500
001 2015036258
003 DLC
005 20151119083208.0
008 150916s2016 flu b 001 0 eng
010 $a 2015036258
020 $a9781498743495 (hardcover : alk. paper)
035 $a(DNLM)101668476
040 $aDNLM/DLC$cDLC$erda$dDLC
042 $apcc
050 00 $aRM301
060 10 $aQV 241
082 00 $a615.1$223
100 1 $aNiazi, Sarfaraz,$d1949- ,$eauthor.
245 10 $aBiosimilars and interchangeable biologics.$pTactical elements /$cSarfaraz K. Niazi.
246 1 $aTactical elements
263 $a1612
264 1 $aBoca Raton :$bTaylor & Francis/CRC Press,$c2016.
300 $ap. ;$ccm.
336 $atext$2rdacontent
337 $aunmediated$2rdamedia
338 $avolume$2rdacarrier
504 $aIncludes bibliographical references and index.
505 0 $aStructural and functional considerations -- Immunogenicity considerations -- Product development strategies -- Stability and formulation considerations -- Establishing biosimilarity -- Recombinant expression systems -- Upstream systems optimization -- Downstream system optimization -- Single use manufacturing systems (SUMS) -- Commercial manufacturing systems -- Outsourcing considerations.
650 12 $aBiosimilar Pharmaceuticals$xstandards.
650 22 $aDrug Approval.
650 22 $aDrug Discovery$xstandards.
650 22 $aDrug Evaluation$xstandards.
650 22 $aDrug Industry$xstandards.